SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001485003-16-000035
Filing Date
2016-01-15
Accepted
2016-01-15 16:30:12
Documents
3
Period of Report
2016-01-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-kxacphase3data.htm 8-K 38331
2 EXHIBIT 99.1 a005acph3prfinal.htm EX-99.1 11642
3 ebiologo.jpg GRAPHIC 15878
  Complete submission text file 0001485003-16-000035.txt   73298
Mailing Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142 617-871-9911
Eleven Biotherapeutics, Inc. (Filer) CIK: 0001485003 (see all company filings)

IRS No.: 252025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36296 | Film No.: 161345790
SIC: 2834 Pharmaceutical Preparations